These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C. Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C; Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528 [TBL] [Abstract][Full Text] [Related]
4. Niacin-based therapy for dyslipidemia: past evidence and future advances. Ito MK Am J Manag Care; 2002 Sep; 8(12 Suppl):S315-22. PubMed ID: 12240703 [TBL] [Abstract][Full Text] [Related]
5. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. Breuer HW Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448 [TBL] [Abstract][Full Text] [Related]
6. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy. Oki JC Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166 [TBL] [Abstract][Full Text] [Related]
8. Management of hypercholesterolaemia in the patient with diabetes. Packard C; Olsson AG Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606 [TBL] [Abstract][Full Text] [Related]
9. Dyslipidaemia in diabetic patients: time for a rethink. Shepherd J Diabetes Obes Metab; 2007 Sep; 9(5):609-16. PubMed ID: 17697054 [TBL] [Abstract][Full Text] [Related]
10. Clinical trials and lipid guidelines for type II diabetes. Prisant LM J Clin Pharmacol; 2004 Apr; 44(4):423-30. PubMed ID: 15051751 [TBL] [Abstract][Full Text] [Related]
11. Management of dyslipidemia in the high-risk patient. Stein EA Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415 [TBL] [Abstract][Full Text] [Related]
12. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus. Udawat H; Goyal RK Indian Heart J; 2001; 53(2):172-6. PubMed ID: 11428472 [TBL] [Abstract][Full Text] [Related]
13. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes. Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276 [TBL] [Abstract][Full Text] [Related]
14. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763 [TBL] [Abstract][Full Text] [Related]
15. Lipids in type 2 diabetes. Laakso M Semin Vasc Med; 2002 Feb; 2(1):59-66. PubMed ID: 16222596 [TBL] [Abstract][Full Text] [Related]
16. Understanding and treating dyslipidemia associated with noninsulin-dependent diabetes mellitus and hypertension. McKenney JM Pharmacotherapy; 1993; 13(4):340-52. PubMed ID: 8361860 [TBL] [Abstract][Full Text] [Related]
17. Advances in drug treatment of dyslipidemia: focus on atorvastatin. Davignon J Can J Cardiol; 1998 May; 14 Suppl B():28B-38B. PubMed ID: 9627539 [TBL] [Abstract][Full Text] [Related]
18. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment]. Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737 [TBL] [Abstract][Full Text] [Related]
19. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Staels B; Maes M; Zambon A Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776 [TBL] [Abstract][Full Text] [Related]
20. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Fazio S Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]